Mechanism of action: Benztropine balliculeVisual mnemonic: Benztropine mascot “Benz-troping Cog gentleman” “red as a beet” → anticholinergic “mad as a hatter” → BBB-crossing anticholinergic
What it isCentral muscarinic and H1 antagonist with dopamine-reuptake inhibition; drug-induced parkinsonism and acute dystonia.
Why this oneReverses acute dystonic reactions rapidly and more reliably than oral alternatives.
What limits itCognitive and peripheral anticholinergic toxicity make long-term use poor; it does not treat and may worsen tardive dyskinesia.
Molecular structure: Benztropine
Benztropine prescription history
Animated chart of estimated U.S. prescriptions per year, Parkinson medicines (1948–2026). Benztropine enters in 1954 (estimated).
FDA-approved for
Parkinson/drug-induced EPS (~1954)
Principal riskAnticholinergic burden and cognitive impairment
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.